

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Richard G. Olsen, et al.
Serial No. 09/125,841
Filed: January 19, 1999
For: Cellular Immunotherapy

)
Examiner Ronald B. Schwadron, Ph.D.
Group Art Unit 1600

COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

**RESPONSE TO NOTICE OF SEQUENCE LISTING REQUIREMENTS
AND AMENDMENT**

Sir:

Responsive to the outstanding Office action mailed on June 15, 2000 (paper no. 8), Applicants submit herewith a computer-readable copy of a Sequence Listing pursuant to 37 C.F.R. § 1.821, et seq., and a paper copy to be added to the specification by amendment submitted on May 2, 2000. The below-signed attorney hereby attests to the fact that the "Sequence Listing" on the enclosed 3.5" computer diskette as submitted herewith is identical to the paper copy of the "Sequence Listing" added to the specification by amendment herein, pursuant to 37 C.F.R. § 1.821(f). By his signature below, the undersigned attests to the fact that no new matter is introduced into the specification by these amendments or this computer-readable copy of the instant Sequence Listing.

RE MARKS

The replacement page submitted herewith comprises a Sequence Listing pursuant to 37 C.F.R. § 1.821 et seq. and the amendments to the specification are made to identify the nucleotide sequences as filed with the SEQ ID Nos. in the Sequence Listing.

Respectfully submitted,

Jerry K. Mueller, Jr.
Reg. No. 27,576
MUELLER AND SMITH, L.P.A.
MUELLER-SMITH BUILDING
7700 Rivers Edge Drive
Columbus, Ohio 43235-1331
Tel.: 614-436-0600
Fax: 614-436-0057
email: patents@infonet.com

Date: July 25, 2000